Summary of the scientific conference on dietary fatty acids and cardiovascular health: conference summary from the nutrition committee of the American Heart Association by Kris-Etherton, P. et al.
Summary of the Scientific Conference on Dietary Fatty
Acids and Cardiovascular Health
Conference Summary From the Nutrition Committee of the
American Heart Association
Conference Planning and Writing Committee
Penny Kris-Etherton, PhD; Stephen R. Daniels, MD, PhD; Robert H. Eckel, MD;
Marguerite Engler, PhD, RN; Barbara V. Howard, PhD; Ronald M. Krauss, MD;
Alice H. Lichtenstein, DSc; Frank Sacks, MD; Sachiko St. Jeor, PhD; Meir Stampfer, MD, DrPH
For the American Heart Association Nutrition Committee Speakers and Discussants
Robert H. Eckel, MD; Scott M. Grundy, MD, PhD; Lawrence J. Appel, MD, MPH; Tim Byers, MD;
Hannia Campos, PhD; Greg Cooney, PhD; Margo A. Denke, MD; Barbara V. Howard, PhD;
Eileen Kennedy, DSc; Ronald M. Krauss, MD; Penny Kris-Etherton, PhD; Alice H. Lichtenstein, DSc;
Peter Marckmann, MD, DSc; Thomas A. Pearson, MD, PhD; Gabriele Riccardi, MD;
Lawrence L. Rudel, PhD; Mike Rudrum, PhD; Frank Sacks, MD; Daniel T. Stein, MD;
Russell P. Tracy, PhD; Virginia Ursin, PhD; Robert A. Vogel, MD; Peter L. Zock, PhD
AHA Members
Terry L. Bazzarre, PhD; Julie Clark, AHA Staff
The objective of this Executive Summary is to provide asynopsis of the research findings presented at the Amer-
ican Heart Association conference “Dietary Fatty Acids and
Cardiovascular Health—Dietary Recommendations for Fatty
Acids: Is There Ample Evidence?” held on June 5–6, 2000,
in Reston, Va. The conference was held to summarize the
current understanding of the effects of fatty acids on risk of
cardiovascular disease (CVD) and cancer, as well as to
identify gaps in our knowledge base that need to be ad-
dressed. There is great interest in learning more about the
biological effects of the individual fatty acids, their role in
chronic disease risk, and their underlying mechanisms of
action. As research advances are made, there is always the
need to question how new findings may be translated into
practice. There is a long history of research providing the
basis for the modification of existing dietary guidelines.
Research findings have been used to verify intake criteria and
are considered along with practical issues of implementation
to establish new guidelines. A substantive body of consistent
evidence sufficient to defend a dietary recommendation or a
change in existing dietary guidance is essential. The confer-
ence highlighted the progress that has been made in under-
standing the biological effects of fatty acids and also ad-
dressed the need to learn more about how different fatty acids
affect the risk of chronic disease, within the context of
refining dietary guidance to further enhance health.
Epidemiological, Clinical Trial, and
Nonhuman Primate Evidence for the
Relationship Between Type of Fat and
Coronary Disease
As study designs have become increasingly rigorous, a
number of megatrends have emerged from the data.1,2 There
is increased emphasis on identifying the type of fat that best
correlates with disease end points. The classic studies of Keys
et al3 and Hegsted et al4 have shown that saturated fatty acids
(ie, those with a carbon chain length of C12:0 to C16:0) raise
total and low-density lipoprotein (LDL) cholesterol levels,
whereas C18:0 and monounsaturated fat (cis C18:1) are
neutral when substituted for carbohydrate, and n-6 polyun-
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saturated fatty acids (PUFAs) lower cholesterol.3,4 More
recent studies have shown that long-chain n-3 fatty acids are
hypotriglyceridemic and trans fatty acids are hypercholester-
olemic. Epidemiological studies have shown that saturated fat
intake is associated with increased risk of coronary heart
disease; the greatest risk reduction is associated with PUFA
intake, and a lesser extent of risk reduction is associated with
monounsaturated fat.1 Both n-6 (linoleic acid) and n-3 (a-
linolenic acid) PUFAs are protective. Trans fatty acids are
strong predictors of increased coronary risk compared with
saturated fat or carbohydrates.1
The paradigm that dietary fats act exclusively via effects
on serum lipids and lipoproteins has been challenged.5–8 The
Lyon Diet Heart Study5 and the Indian Heart Study6 have
both shown in clinical trials that diet can prevent fatal and
nonfatal cardiovascular events in individuals with CVD. In
both trials, saturated fats were replaced with monounsaturated
fats and a-linolenic acid, an n-3 PUFA that is present in
canola (rapeseed) oil. Vegetables and fruits were increased in
the diets in these studies as well. In addition, fish and fish oil
have been shown to reduce all-cause mortality7,8 and cardio-
vascular death8 in patients who had myocardial infarction.
Studies have been conducted in primates to examine the
effects of dietary fatty acids on atherosclerosis.9,10 Diets with
saturated, monounsaturated, and polyunsaturated (including
both n-3 and n-6) fatty acids have been evaluated. Coronary
artery atherosclerosis (as measured by intimal area) was less
in the polyunsaturated fat than in the saturated fat and
monounsaturated fat groups. Monkeys fed monounsaturated
fat developed equivalent amounts of coronary artery athero-
sclerosis as those fed saturated fat.9 LDL cholesterol was
similar in monkeys fed polyunsaturated and monounsaturated
fat and lower than in animals fed saturated fat. However,
there was an enrichment of cholesteryl oleate in plasma
cholesteryl esters of the monkeys fed the diet high in
monounsaturated fatty acids, which correlated with coronary
artery cholesteryl ester concentration, a measure of coronary
artery atherosclerosis.10 Activation of ACAT2 (the enzyme
responsible for cholesterol oleate formation and secretion by
the liver) may explain how dietary monosaturated fat pro-
motes atherosclerosis out of proportion to its effects on
plasma LDL cholesterol levels. Both n-6 PUFAs (primarily
linoleic acid) and n-3 PUFAs (principally eicosapentaenoic
acid and docosahexaenoic acid) have been shown to confer
protection. That a diet rich in monounsaturated fat resulted in
more atherosclerosis than a diet rich in polyunsaturated fat
even though plasma LDL and high-density lipoprotein (HDL)
cholesterol levels were comparable also suggests that non-
lipid risk factors may play a role in atherogenesis. Thus,
additional studies with cardiovascular end points that go
beyond the measurement of surrogate markers of CVD risk
(ie, plasma lipids and lipoproteins) are needed to evaluate the
effects of fatty acids in humans. In this regard, there is
evidence in human subjects that a single high-fat meal (high
in monounsaturated fat or saturated fat) adversely affects
endothelial function,11 which is thought by some to be an
early event in the atherogenic process.
Epidemiological and Clinical Trial Evidence
for a Relationship Between Type of Fat and
Cancer Risk
There are no good biomarkers for studying the link
between cancer risk and fatty acids in the diet.12 Epidemi-
ological studies relating dietary fats to cancer risk have
generally shown weak and inconsistent patterns of associ-
ations. Breast cancer risk has been shown to be unrelated
to fat content of the diet across a wide range of intake.
There is limited evidence that monounsaturated fats might
be associated with reduced risk and that trans fats might be
associated with increased risk of breast cancer, but those
findings are weak and should be regarded as preliminary.
Prostate cancer has been associated with higher dietary
saturated fat, an association that may be due to an effect of
saturated fat on circulating testosterone levels. Colorectal
cancer risk is increased with higher-fat diets, but this
association may be due more to a direct effect of red meats
or carcinogens formed with high-temperature cooking of
meats than to fat per se. There is limited information from
randomized, controlled trials of cancer end points. The
Polyp Prevention Trial13 showed that reducing the levels of
fat in the diet from 36% to 24% did not reduce the rate of
new adenoma formation over a 3-year period. However,
because the low-fat group did not show a decrease in
plasma cholesterol and HDL cholesterol, established mark-
ers of reduced total fat intake, the lack of an effect on
polyp formation may have been due to a lack of adherence
to the low-fat diet. Additional long-term studies of fatty
acids and cancer are needed.
Effects of Fatty Acids on Insulin Secretion
and Action
The insulinotropic effect of individual fatty acids increases
and decreases dramatically with chain length and degree of
unsaturation, respectively.14 According to studies designed
to examine the influence of individual fatty acids on
insulin secretion in the perfused rat pancreas, insulin
release was as follows: octanoate (C8:0), 3.4-fold increase;
linoleate (C18:2 cis/cis), 5.3-fold increase; oleate (C18:1
cis), 9.4-fold increase; palmitate (C16:0), 16.2-fold in-
crease; and stearate (C18:0), 21.0-fold increase.14 Insulin
release was increased 3.1-fold by palmitoleate (C16:1 cis).
Only a modest effect on insulin release was observed with
a cis3 trans switch of the double bond in the C16:1 and
C18:1 fatty acids. Thus, there is remarkable diversity in
how individual fatty acids affect insulin secretion. Conse-
quently, these in vitro studies suggest that the type and
amount of circulating fatty acids may determine the insulin
secretory response. Importantly, saturated fat raises insulin
resistance. Unpublished data from a multicenter study in
Europe showed that individuals were more insulin sensi-
tive when consuming a diet high in monounsaturated fatty
acids than when consuming an equivalent diet high in
saturated fat.
Increased intake of dietary fat reduces insulin action in
experimental animals, and this insulin resistance is associated
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with the accumulation of triglyceride in muscle and liver. In
animal models, high-fat diets composed of fish oil or saf-
flower oil have markedly different effects on insulin action,
and these differences may depend on the ability of fatty acids
in fish oil to upregulate lipid oxidation in the liver. Mecha-
nisms may involve increased translocation and activation of
specific protein kinase C isozymes (PKC-e and PKC-u) that
phosphorylate and reduce the activity of insulin signaling
intermediates.15,16 In C2C12 cells (a murine muscle cell line),
oleate and palmitate have different effects on insulin-
stimulated glucose conversion to glycogen and different
effects on key components of the insulin signaling path-
ways.17 On the other hand, in humans, varying the total fat
content of the diet does not affect insulin-mediated glucose
disposal.18 However, it is becoming increasingly evident that
specific fatty acids or their derivatives may have roles other
than as energy substrates involving regulation of enzyme
activity and gene expression in insulin-responsive tissues.
More in vivo studies in humans are needed.
Effects of Fatty Acids on Hemostatic Factors
and Platelet Function
Thrombosis is an important aspect of CVD. The coagula-
tion system, which includes platelets and coagulation
proteins, plays a role in the evolution of atheroma and in
the events that follow rupture of a plaque that leads to
thrombosis and symptomatic disease. As the importance of
hemostatic factors has become clear, the question of
whether diet may influence them has been one focus of
research.
Several hemostatic factors are influenced by dietary
components.19,20 For example, when a high-fat diet is
replaced by a lower-fat, higher-fiber diet, the activity of
factor VII decreases and the capacity of the endogenous
fibrinolytic system increases. Studies of the relationship of
dietary fatty acids and hemostatic factors generally show
that hemostatic proteins are not affected by changes in the
type of dietary fat, such as saturated, monounsaturated,
trans, or n-6 polyunsaturated fats.
Platelets play several roles in atherosclerosis, including
exacerbating the atherosclerotic process, adhering to rup-
tured or eroded lesions, and participating in the formation
of an occlusive thrombus. Lipids are an important constit-
uent of the platelet membrane. Lipids are also important in
the intracellular signaling of platelets. Many studies have
explored the relationship of dietary fatty acids and platelet
function. The majority of studies have been performed in
small numbers of human subjects and in animal models.
However, interpretation of results is difficult because
different methods have been used to estimate platelet
function, there has been inconsistency in assessment of
platelet lipid composition, and there have been questions
regarding the relationship of in vitro assays to in vivo
activity. The composition and duration of the dietary
manipulations have been inconsistent across studies. There
are few population-based epidemiological data because of
difficulty in assessing platelet function and diet composi-
tion in these studies.
In general, the composition of the platelet membrane
appears to reflect the fatty acid composition of the diet.
Diets rich in n-3 fatty acids appear to cause platelets to
aggregate less at a fixed dose of agonist or to require more
agonist to aggregate. There are some data to support a
deleterious effect of dietary stearic acid on platelet aggre-
gation. It appears that within the context of the usual diet,
there may be some effects of dietary fatty acids on both the
coagulation proteins and the platelet membrane. However,
these effects are minor, and the clinical meaning of such
effects is unclear.
Effects of Fatty Acids on Blood Pressure
Evidence from laboratory investigations, observational
studies, and clinical trials indicates that supplementation of
a diet with high doses of n-3 PUFAs (commonly found in
fish oil) can reduce blood pressure.21,22 However, large
quantities (eg, 3 g per day) are needed to see a minimal
effect in nonhypertensive individuals and only very modest
effects in hypertensive individuals. The most effective n-3
PUFA is docosahexaenoic acid rather than eicosapenta-
enoic acid. Given the quantities needed to achieve the
desired effect, this is not a practical treatment for lowering
blood pressure. Short-term changes in consumption of
saturated fat or n-6 PUFAs appear to have little effect on
blood pressure, although there is some suggestion that a
diet rich in monounsaturated fatty acids can lower blood
pressure. Regular fish consumption may also reduce blood
pressure; in addition, the effect of fish oil consumption
with weight loss is additive in reducing blood pressure.
Fatty Acids and Endothelial Activation
In vitro studies have been conducted to assess the effects
of long-chain fatty acids on leukocytic-endothelial inter-
actions that play a role in atherogenesis and inflamma-
tion.23 These interactions are mediated importantly by
factors that regulate expression of leukocyte adhesion
molecules. There is recent evidence that the n-3 fatty acid
docosahexaenoic acid reduces endothelial expression of
vascular cell adhesion molecule-1 (VCAM-1), E-selectin,
intercellular adhesion molecule-1 (ICAM-1), interleukin 6
(IL-6), and IL-8 in response to exposure to IL-1, IL-4,
tumor necrosis factor, or bacterial endotoxin.23 In contrast,
saturated fatty acids had no inhibitory effects. In addition,
there was a progressive increase in inhibitory activity with
fatty acids of the same chain length but increasing in
degree of unsaturation. Thus, n-3 fatty acids seem to have
the greatest inhibitory effect, with n-6 fatty acids being
intermediate, followed by monounsaturated fatty acids.
The emerging evidence suggests that with increasing fatty
acid unsaturation, there is an accompanying increase in
inhibition of endothelial activation.
Dietary Fat Intake
The US Department of Agriculture has been monitoring
consumption patterns in the United States for over 50 years
1036 Circulation February 20, 2001
using representative samples of the population.24 Con-
sumption trends over the past 30 years have shown a
general downward trend in energy consumption from 1965
to 1995. This downward trend in energy intake has been
paralleled by a decrease in the percent of energy provided
by total fat and saturated fat in the diet. When the period
1989 to 1991 is compared with 1994 to 1996, the data
show a slight upward trend in energy consumption for
certain age/gender groups; it is unclear how much of this is
a result of a more accurate measurement as opposed to a
true increase in kilocalorie intake. Some differences across
racial/ethnic and socioeconomic groups were noted: blacks
had a slightly higher intake of total fat and saturated fat,
intake and there was a modest decrease in fat and saturated
fat intake with increasing income.
Because of challenges associated with collecting accu-
rate food consumption data, there is a pressing need to
identify reliable markers of fat and fatty acid intake.
Evidence indicates that adipose tissue fatty acid composi-
tion is a suitable biomarker for habitual type of dietary fat
intake.25,26
Modification of Oils for Improved
Health Benefits
The production of genetically modified oilseed crops to
provide vegetable oils with modified lipids provides a
convenient mechanism to deliver healthier products to
consumers without requiring them to make significant
dietary changes.27 Examples of such modified oils include
low-saturated fat and zero-saturated fat soybean and
canola oils, canola oil that contains medium-chain fatty
acids, high-stearate canola oil (for trans fatty acid–free
products), high oleic acid soybean oil, and canola oil
containing the long-chain PUFAs, g-linolenic (18:3 n-6)
and stearidonic acids (18:4 n-3). Long-chain n-3 fatty acids
in the form of stearidonic acids, the 18:4 n-3 precursor to
eicosapentaenoic acid and docosahexaenoic acid, could
provide a more effective n-3 fatty acid than a-linolenic
acid. In addition, vegetable oil– derived stearidonic acids
could be used as an alternative to fish oil to provide
long-chain n-3 fatty acids with enhanced stability and taste
that can be incorporated into a wide variety of foods.
Dietary Fat Recommendations: Where We
Are and Where We Could Go
Current dietary guidance in general recommends a diet that
contains #30% of energy as fat, #10% of energy as
saturated fatty acids, up to 10% of energy as PUFAs, and
,300 mg of cholesterol per day.28 –30 These recommenda-
tions are coupled with guidance on physical activity and
weight maintenance and are distinct from those for indi-
viduals with specific metabolic profiles that might neces-
sitate more restrictive or targeted regimens. In the current
revisions of the recommendations, increased recognition is
placed on the diet as a whole and away from segmented
guidance on individual dietary components. In effect, this
shifts the emphasis from the question of what not to
consume to what to consume. A more comprehensive
approach to dietary guidance will likely reduce the risk of
overemphasis on one component of the guidelines over
another, allow for a stronger message regarding other
aspects of lifestyle (eg, body weight maintenance and
regular exercise), and support the necessity of the dietary
guidelines/lifestyle approach to disease risk reduction as a
lifelong endeavor.
Conclusions
Individual fatty acids have remarkably diverse effects on
risk factors for CVD. With respect to effects on lipids and
lipoproteins, we have a reasonably good understanding of
the effects of individual fatty acids. Much remains to be
learned about individual fatty acids with regard to other
risk factors such as hemostatic factors, platelet function,
blood pressure, and endothelial function, as well as the
development of atherosclerosis. In general, the unsaturated
fatty acids (excluding trans fatty acids) favorably affect a
number of factors that are cardioprotective. Unsaturated
fatty acids lower total and LDL cholesterol levels when
substituted for saturated fatty acids (C12:0 to C16:0).
Long-chain n-3 fatty acids from fish oil decrease triglyc-
eride levels, favorably affect platelet function, and de-
crease blood pressure slightly in hypertensive individuals.
Oleic acid has been shown to decrease postprandial factor
VII activity. Epidemiological studies have shown benefi-
cial effects of unsaturated fatty acids (both polyunsaturated
and monounsaturated) compared with saturated fatty acids
on incidence of coronary disease. Controlled clinical trials
have demonstrated beneficial effects of diets high in n-6
and n-3 fatty acids on coronary heart disease. There is
some evidence to suggest potentially adverse effects of
unsaturated fatty acids in that monounsaturated fat has
atherogenic effects in monkeys that are comparable to
those of saturated fat.
Technologies are emerging that will enable the produc-
tion of designer fats and oils that have a modified fatty acid
profile that provides both nutritional and processing ben-
efits. Based on a large body of evidence, it is apparent that
the optimal diet for reducing risk of chronic diseases is one
in which saturated fatty acids are reduced and trans fatty
acids from manufactured fats are virtually eliminated.
Because of the growing health benefits recognized for
unsaturated fatty acids, it is likely that a mixture of these
fatty acids in the diet will confer the greatest health
benefits within the context of a total fat intake that is
considered moderate. Given the limited amount of evi-
dence to date on the effect of individual fatty acids on
many of the variables discussed in this meeting summary,
it is not possible to incorporate specific advice on all the
points raised into population-wide dietary guidelines. As
the evidence base strengthens, it will be important to
reevaluate the current guidelines on a regular basis and
modify them, if necessary, in light of substantive new
findings.
Kris-Etherton et al Dietary Fatty Acids and Cardiovascular Health 1037
Appendix
Fatty Acids Conference, June 5 to June 6, 2000,
Reston, Virginia: Faculty
Welcome/Opening Remarks, Discussant: Penny Kris-Etherton, PhD,
Distinguished Professor of Nutrition, Penn State University, Univer-
sity Park, Pa.
Welcome/Opening Remarks, Discussant, and Conference Dis-
cussion (Closing): Robert H. Eckel, MD, University of Colorado,
Health Sciences Center, Division of Endocrinology, Denver,
Colo.
Overview: Rationale for Dietary Fat Guidelines: Scott M.
Grundy, MD, PhD, University of Texas Southwestern Medical
Center at Dallas, Dallas, Tex.
Analysis and Interpretation of the Epidemiological and Clini-
cal Trial Scientific Evidence for Fatty Acid Relationships/Effects
on Disease End Points: Thomas A. Pearson, MD, PhD, Depart-
ment Chair, Community and Preventive Medicine, Albert D.
Kaiser Professor, University of Rochester, Rochester, NY.
Epidemiological and Clinical Trial Evidence for the Relation-
ship Between Type of Fat and CVD Risk: Frank Sacks, MD,
Associate Professor of Nutrition, Harvard School of Public
Health, Department of Nutrition, Boston, Mass; Tim Byers, MD,
Professor, Department of Preventive Medicine and Biometrics,
University of Colorado School of Medicine, Denver, Colo.
Fatty Acids in Atherosclerosis: Lawrence L. Rudel, PhD, Department of
Pathology, Wake Forest University School of Medicine, Section of Com-
parative Medicine, Winston-Salem, NC.
Effects of Fatty Acids on Lipids and Lipoproteins: Margo A.
Denke, MD, Associate Professor, University of Texas Southwest-
ern Medical Center at Dallas, Dallas, Tex.
General Discussion and AHA Dietary Guidelines: Ronald M.
Krauss, MD, Senior Scientist and Head of the Molecular Medi-
cine Department, University of California at Berkeley, Lawrence
Berkeley National Laboratory, Berkeley, Calif.
Insulin Secretion: Daniel T. Stein, MD, Albert Einstein College
of Medicine, Bronx, NY.
Insulin Action: Greg Cooney, PhD, Senior Research Fellow,
Metabolism and Diabetes Program, Garvan Institute of Medical
Research, St. Vincent’s Hospital, Sydney, Australia.
Hemostatic Factors: Peter Marckmann, MD, DSc, Associate
Professor, Research Department of Human Nutrition, The Royal
Veterinary and Agricultural University, Frederiksberg, Denmark.
Platelet Function: Russell P. Tracy, PhD, Professor of Pathol-
ogy and Biochemistry, Director, Laboratory for Clinical Bio-
chemistry Research, University of Vermont, Colchester, Vt.
Vascular Reactivity: Robert A. Vogel, MD, Herbert Berger
Professor of Medicine and Head, Division of Cardiology, Depart-
ment of Medicine, University of Maryland School of Medicine,
Baltimore, Md.
Blood Pressure: Lawrence J. Appel, MD, MPH, The Johns
Hopkins University, Baltimore, Md.
Fatty Acids in the Diet and Food Supply: Eileen Kennedy, DSc,
United States Department of Agriculture, Office of Research,
Education & Economics, Washington, DC.
Biomarkers to Assess Fatty Acid Intake: Hannia Campos, PhD,
Assistant Professor, Harvard School of Public Health, Department
of Nutrition, Boston, Mass.
New Technologies to Manipulate Dietary Fatty Acids: Virginia
Ursin, PhD, Nutrition Sector, Monsanto Company, Calgene
Campus, Davis, Calif.
Technologies to Modify Fatty Acids: Mike Rudrum, PhD,
Unilever Research Vlaardingen, Vlaardingen, The Netherlands.
Discussant: Barbara V. Howard, PhD, President, Medlantic Re-
search Institute, Washington, DC.
Dietary Recommendations for Fatty Acids: Peter L. Zock, PhD,
Wageningen Center for Food Sciences, Nutrition and Health
Program, Wageningen University, Wageningen, The Netherlands.
Dietary Recommendations for Fatty Acids: Gabriele Riccardi,
MD, Institute of Internal Medicine and Metabolic Diseases,
Second Medical School, University of Naples, Napoli, Italy.
Recommendations for Dietary Fat: Where We Are and Where
We Could Go: Alice H. Lichtenstein, DSc, Professor of Nutrition,
HNRC/Tufts University, Boston, Mass.
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